Even so, previous studies have shown high concordance between plasma- and tissue-based genotyping in BC (32–34), and plasma–based PIK3CA testing is now recognized as a clinically supported option when tumor tissue is unavailable (21). This evidence concerns the gene PIK3CA and breast cancer.